Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) had its price target lifted by analysts at Citigroup Inc. from $154.00 to $155.00 in a report released on Tuesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup Inc.’s price objective indicates a potential upside of 17.66% from the company’s previous close.

A number of other research analysts have also commented on the company. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $185.00 price target on shares of Alexion Pharmaceuticals in a research report on Tuesday, August 16th. Morgan Stanley reaffirmed an “overweight” rating on shares of Alexion Pharmaceuticals in a research report on Wednesday, June 29th. Vetr upgraded Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $146.84 target price on the stock in a report on Thursday, August 25th. Royal Bank Of Canada assumed coverage on Alexion Pharmaceuticals in a report on Tuesday, July 12th. They set an “outperform” rating and a $188.00 target price on the stock. Finally, Credit Suisse Group AG upgraded Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating and reduced their target price for the stock from $186.00 to $165.00 in a report on Monday, July 11th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company. Alexion Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $182.85.

Alexion Pharmaceuticals (NASDAQ:ALXN) traded up 0.42% on Tuesday, hitting $131.73. The stock had a trading volume of 1,136,965 shares. The company has a market cap of $29.54 billion, a P/E ratio of 330.98 and a beta of 1.08. Alexion Pharmaceuticals has a 1-year low of $110.56 and a 1-year high of $193.45. The stock has a 50 day moving average price of $131.30 and a 200 day moving average price of $135.95.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/citigroup-inc-raises-alexion-pharmaceuticals-inc-alxn-price-target-to-155-00.html

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.13 EPS for the quarter, missing analysts’ consensus estimates of $1.17 by $0.04. The business had revenue of $753 million for the quarter, compared to the consensus estimate of $743.18 million. Alexion Pharmaceuticals had a net margin of 3.19% and a return on equity of 10.02%. The company’s revenue for the quarter was up 18.4% on a year-over-year basis. During the same period in the previous year, the company earned $1.44 EPS. On average, equities research analysts expect that Alexion Pharmaceuticals will post $4.65 EPS for the current fiscal year.

In other news, Director Leonard Bell sold 1,010 shares of the stock in a transaction on Monday, August 8th. The stock was sold at an average price of $137.14, for a total transaction of $138,511.40. Following the transaction, the director now directly owns 405,289 shares of the company’s stock, valued at approximately $55,581,333.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Carsten Thiel sold 1,000 shares of the stock in a transaction on Tuesday, September 6th. The shares were sold at an average price of $125.94, for a total value of $125,940.00. Following the transaction, the executive vice president now directly owns 40,579 shares in the company, valued at $5,110,519.26. The disclosure for this sale can be found here. Company insiders own 4.41% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. purchased a new position in Alexion Pharmaceuticals during the first quarter valued at $114,000. NEXT Financial Group Inc boosted its position in Alexion Pharmaceuticals by 66.1% in the second quarter. NEXT Financial Group Inc now owns 1,106 shares of the biopharmaceutical company’s stock valued at $129,000 after buying an additional 440 shares during the last quarter. Bellwether Investment Group LLC purchased a new position in Alexion Pharmaceuticals during the second quarter valued at $172,000. Charlemagne Capital Ltd. purchased a new position in Alexion Pharmaceuticals during the second quarter valued at $191,000. Finally, Evercore Wealth Management LLC boosted its position in Alexion Pharmaceuticals by 5.0% in the second quarter. Evercore Wealth Management LLC now owns 1,735 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 83 shares during the last quarter. 96.38% of the stock is currently owned by hedge funds and other institutional investors.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.